[go: up one dir, main page]

MX2015015537A - Formulacion de pastillas de nicotina. - Google Patents

Formulacion de pastillas de nicotina.

Info

Publication number
MX2015015537A
MX2015015537A MX2015015537A MX2015015537A MX2015015537A MX 2015015537 A MX2015015537 A MX 2015015537A MX 2015015537 A MX2015015537 A MX 2015015537A MX 2015015537 A MX2015015537 A MX 2015015537A MX 2015015537 A MX2015015537 A MX 2015015537A
Authority
MX
Mexico
Prior art keywords
synthetic
nicotine lozenge
lozenge formulation
nicotine
semi
Prior art date
Application number
MX2015015537A
Other languages
English (en)
Inventor
Satish Ramchandra Dipali
Sumeet Bindra Narang
Shadab Ahmad Pathan
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2015015537A publication Critical patent/MX2015015537A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Aspectos de la presente invención se dirigen a una pastilla de nicotina para administración oral que comprende: un principio activo de nicotina; al menos un polímero de alta viscosidad, soluble en agua, sintético o semisintético, no iónico; y al menos un polímero de baja viscosidad, soluble en agua, sintético o semisintético, no iónico; las pastillas de la presente invención son más estables y menos caras que las pastillas tradicionales.
MX2015015537A 2013-05-10 2014-05-09 Formulacion de pastillas de nicotina. MX2015015537A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1398DE2013 2013-05-10
PCT/US2014/037421 WO2014182983A1 (en) 2013-05-10 2014-05-09 Nicotine lozenge formulation

Publications (1)

Publication Number Publication Date
MX2015015537A true MX2015015537A (es) 2016-02-09

Family

ID=51867761

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015537A MX2015015537A (es) 2013-05-10 2014-05-09 Formulacion de pastillas de nicotina.

Country Status (12)

Country Link
US (1) US20160113868A1 (es)
EP (1) EP2994136B1 (es)
JP (1) JP2016518413A (es)
CN (1) CN105263493A (es)
AR (1) AR096223A1 (es)
AU (2) AU2014262579B2 (es)
BR (1) BR112015028302A2 (es)
CA (1) CA2912223C (es)
DK (1) DK2994136T3 (es)
MX (1) MX2015015537A (es)
TW (1) TW201507726A (es)
WO (1) WO2014182983A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170172995A1 (en) * 2015-09-08 2017-06-22 Venkateswara Rao Repaka Pharmaceutical compositions of Nicotine and process for preparation thereof
WO2019244176A1 (en) * 2018-06-23 2019-12-26 Strides Shasun Limited Stable nicotine lozenges
CN112444466B (zh) * 2019-09-05 2023-02-28 上海新型烟草制品研究院有限公司 一种用于评价口含烟烟碱体外吸收的方法
EP4627940A1 (en) * 2024-04-04 2025-10-08 Nicoventures Trading Limited Compositions and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
GB8615676D0 (en) 1986-06-26 1986-07-30 Stoppers Co Ltd Nicotine containing lozenge
US5110605A (en) 1990-08-21 1992-05-05 Oramed, Inc. Calcium polycarbophil-alginate controlled release composition and method
US5135753A (en) * 1991-03-12 1992-08-04 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5549906A (en) 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5362496A (en) 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
HU224035B1 (hu) 1996-05-13 2005-05-30 Novartis Consumer Health S.A. Bukkális adagolórendszer
US6358060B2 (en) * 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
EP1372392A4 (en) * 2001-03-26 2004-06-23 Smithkline Beecham Corp ORAL DOSAGE FORM CONTAINING NICOTINE
ES2708552T3 (es) * 2002-12-20 2019-04-10 Niconovum Ab Método para la preparación de un material particulado que contiene nicotina con una celulosa cristalina (en particular MCC)
US7470397B2 (en) * 2003-10-24 2008-12-30 Adhesives Research, Inc. Disintegratable films for diagnostic devices
CN101437497A (zh) * 2006-03-16 2009-05-20 尼科诺瓦姆股份公司 提供迅速释放尼古丁的口香糖组合物
US20100061940A1 (en) 2006-03-16 2010-03-11 Niconovum Ab Chewing Gum Compositions Providing Rapid Release of Nicotine
US20080260836A1 (en) * 2007-04-18 2008-10-23 Thomas James Boyd Films Comprising a Plurality of Polymers
AR071420A1 (es) * 2008-05-01 2010-06-16 Smithkline Beecham Corp Composicion de pastilla para chupar oral que comprende un principio activo de nicotina y procedimiento para fabricarla
PH12012502463A1 (en) * 2010-06-30 2019-06-03 Colgate Palmolive Co Multilayer films for delivery of flavor
US20140065213A1 (en) * 2011-05-06 2014-03-06 GlaxoSmithKline, LLC Sustained Release Paracetamol Formulations

Also Published As

Publication number Publication date
CA2912223A1 (en) 2014-11-13
JP2016518413A (ja) 2016-06-23
EP2994136A1 (en) 2016-03-16
WO2014182983A1 (en) 2014-11-13
BR112015028302A2 (pt) 2017-07-25
DK2994136T3 (da) 2021-02-01
AR096223A1 (es) 2015-12-16
EP2994136B1 (en) 2020-11-18
AU2017203121A1 (en) 2017-06-01
AU2014262579B2 (en) 2017-06-01
AU2014262579A1 (en) 2015-11-26
CA2912223C (en) 2021-08-31
CN105263493A (zh) 2016-01-20
AU2017203121B2 (en) 2019-02-21
EP2994136A4 (en) 2016-10-26
TW201507726A (zh) 2015-03-01
US20160113868A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
AU2019268062A1 (en) Benzoquinolone inhibitors of VMAT2
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX2016008448A (es) Conjugados de var2csa-farmaco.
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX364069B (es) Moduladores de la proteína activadora de 5-lipoxigenasa.
MY195343A (en) A Novel Phtalazinone Derivatives and Manufacturing Process Thereof
NZ710291A (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
UA115357C2 (uk) Похідні піридин-4-ілу
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
MX368268B (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
MX2015015537A (es) Formulacion de pastillas de nicotina.
MX2015016603A (es) Composiciones de corticosteroides.
WO2015044434A3 (de) FLUOR-9-METHYL-ß-CARBOLINE
MX2016003230A (es) Complejo lubricante para la boca.
GEP201706769B (en) Composition of tiacumicin compounds
IN2013MU03309A (es)
IN2013CH04314A (es)
WO2014122671A3 (en) Solid oral compositions of saxagliptin
IN2013MU03422A (es)
IN2014KN02584A (es)
IN2013CH02437A (es)